v3.20.4
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Net sales $ 224,253 $ 184,934 $ 428,452 $ 368,177
Cost of sales 73,353 63,531 139,821 128,361
Gross margin 150,900 121,403 288,631 239,816
Operating expenses:        
Selling, general and administrative 83,116 68,030 155,714 137,040
Research and development 16,789 16,381 32,830 32,459
Total operating expenses 99,905 84,411 188,544 169,499
Operating income 50,995 36,992 100,087 70,317
Other (expense) income 5,373 113,334 (4,381) 97,812
Earnings before income taxes 56,368 150,326 95,706 168,129
Income taxes 10,224 30,704 16,168 34,111
Net earnings, including noncontrolling interest 46,144 119,622 79,538 134,018
Net earnings attributable to noncontrolling interest (130) 0 (130) 0
Net earnings attributable to Bio-Techne 46,274 119,622 79,668 134,018
Other comprehensive (loss) income:        
Foreign currency translation adjustments 16,928 11,867 28,842 4,265
Derivative instruments - cash flow hedges 2,059 1,408 4,202 904
Other comprehensive income (loss) 18,987 13,275 33,044 5,169
Other comprehensive income attributable to noncontrolling interest 83 0 83 0
Other comprehensive income attributable to Bio-Techne 18,904 13,275 32,961 5,169
Comprehensive income attributable to Bio-Techne $ 65,178 $ 132,897 $ 112,629 $ 139,187
Earnings per share attributable to Bio-Techne:        
Basic (in dollars per share) $ 1.20 $ 3.13 $ 2.06 $ 3.51
Diluted (in dollars per share) $ 1.15 $ 3.02 $ 1.98 $ 3.40
Weighted average common shares outstanding:        
Basic (in shares) 38,691 38,167 38,614 38,100
Diluted (in shares) 40,257 39,550 40,135 39,370

Source